E-LIB Suche - Ergebnisse für: Komrokji, Rami S.

1

Hypomethylating Agents and Venetoclax for Acute Myeloid Leu..:

Ionescu, Filip ; David, Jerel C. ; Ravichandran, Apoorva...
Clinical Lymphoma Myeloma and Leukemia. 24 (2024) 6 - p. 400-406 , 2024

Link: https://doi.org/10.1016/..

2

Safety and efficacy of luspatercept for the treatment of an..:

Gerds, Aaron T. ; Harrison, Claire N. ; Kiladjian, Jean-Jacques...
Blood Advances. , 2024

Link: https://doi.org/10.1182/..

3

Imetelstat in patients with lower-risk myelodysplastic synd..:

Platzbecker, Uwe ; Santini, Valeria ; Fenaux, Pierre...
The Lancet. 403 (2024) 10423 - p. 249-260 , 2024

Link: https://doi.org/10.1016/..

4

POSTER: MDS-234 Reduction of Transfusion Burden (TB), Hemog..:

Komrokji, Rami S. ; Platzbecker, Uwe ; Porta, Matteo Della...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S184 , 2023

Link: https://doi.org/10.1016/..

5

An agenda to advance research in myelodysplastic syndromes:..:

Stahl, Maximilian ; Abdel-Wahab, Omar ; Wei, Andrew H....
Blood Advances. 7 (2023) 12 - p. 2709-2714 , 2023

Link: https://doi.org/10.1182/..

6

Efficacy and safety of luspatercept versus epoetin alfa in ..:

Platzbecker, Uwe ; Della Porta, Matteo Giovanni ; Santini, Valeria...
The Lancet. 402 (2023) 10399 - p. 373-385 , 2023

Link: https://doi.org/10.1016/..

7

Clinical characteristics and outcomes of EZH2-mutant myelod..:

Ball, Somedeb ; Aguirre, Luis E. ; Jain, Akriti G....
Leukemia Research. 124 (2023) - p. 106999 , 2023

Link: https://doi.org/10.1016/..

8

Improved benefit of continuing luspatercept therapy: sub-an..:

Germing, Ulrich ; Fenaux, Pierre ; Platzbecker, Uwe...
Annals of Hematology. 102 (2023) 2 - p. 311-321 , 2023

Link: https://doi.org/10.1007/..

9

PB2221: AN OPEN-LABEL, PHASE 1/1B STUDY TO EVALUATE THE SAF..:

Kuykendall, Andrew ; Bradley, Terrence ; Komrokji, Rami S....
HemaSphere. 7 (2023) S3 - p. e906057e , 2023

Link: https://doi.org/10.1097/..

10

MDS-157 Luspatercept Versus Epoetin Alfa (EA) for Treatment..:

Garcia-Manero, Guillermo ; Platzbecker, Uwe ; Santini, Valeria...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S355-S356 , 2023

Link: https://doi.org/10.1016/..

11

PB2003: REAL-WORLD TREATMENT PATTERNS OF PATIENTS (PTS) WIT..:

Komrokji, Rami S. ; Hernandez- Donoso, Leyla ; Hodzic, Sejla...
HemaSphere. 7 (2023) S3 - p. e564327b , 2023

Link: https://doi.org/10.1097/..

12

Long-term utilization and benefit of luspatercept in transf..:

Platzbecker, Uwe ; Santini, Valeria ; Komrokji, Rami S....
Leukemia. 37 (2023) 11 - p. 2314-2318 , 2023

Link: https://doi.org/10.1038/..

13

POSTER: MPN-498 Addition of Navitoclax to Ruxolitinib for M..:

Pemmaraju, Naveen ; Somervaille, Tim C.P. ; Palandri, Francesca...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S193 , 2023

Link: https://doi.org/10.1016/..

14

Activity of luspatercept and ESAs combination for treatment..:

Komrokji, Rami S. ; Aguirre, Luis E. ; Al Ali, Najla H....
Blood Advances. 7 (2023) 14 - p. 3677-3679 , 2023

Link: https://doi.org/10.1182/..

15

Drivers of deep molecular response and long‐term outcomes i..:

Patel, Parth C. ; Ball, Somedeb ; Jain, Akriti G....
American Journal of Hematology. 98 (2023) 12 - p. , 2023

Link: https://doi.org/10.1002/..